By John Leavitt, Ph.D. Nerac Analyst
Originally Published July 21, 2014
Such a protein appears to be described in a paper published in the journal Molecular Cancer Therapeutics in February 2014 by Heinz-Josef Lenz at the Keck School of Medicine of the University of Southern California in collaboration with colleagues at the University of Graz in Austria. Dr. Lenz talks about the importance of molecular analysis of tumors in this video. The protein Lenz and colleagues describe is plastin which exists in two alternative isoforms in a wide variety of human cancer cells – L-plastin (LCP1) and T-plastin (PLS3). Dr. Lenz’s group has discovered that inherited genetic polymorphisms in these two genes significantly affect the time of tumor recurrence in colorectal cancer after resection and chemotherapy.
- 62By John Leavitt, Ph.D. Nerac Analyst Originally Published: August 12, 2014 In 1987, my colleagues at Stanford and I published a paper that clearly demonstrated that expression of a charge-altered mutant human beta-actin (glycine to aspartic acid substitution at amino acid 245; G245D) caused non-tumorigenic, immortalized human fibroblasts to form aggressive tumors in nude mice (Leavitt…
- 36"Merck wouldn't have done this if there wasn't very good preliminary results from the clinical trials," said Dr. John Leavitt, a senior biotech analyst with the research firm Nerac. "There must be some trial data that is being shared with Merck by NewLink on the progress of these clinical trials." Read the full Des Moines…
- 30New analyst brings extensive experience in engineering, energy and environmental systems Read the full release here.